Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Most End-of-Life Costs for Patients with Cancer Are Not Drug Related

TOP - September 2011 Vol 4, No 6 published on September 21, 2011 in Conference Correspondent
Wayne Kuznar

CHICAGO—Most end-of-life costs ac - crued by patients with cancer are related to health services rather than the use of drugs, according to an analysis of claims from a large health plan (UnitedHealth).

“The bottom line is that most of the costs were not related to drugs but to healthcare services plus the inpatient hospitalizations,” said April Teitelbaum, MD, coinvestigator and a practicing oncologist and Senior Medical Director, Life Sciences, Hematology/ Oncology, Innovus, Eden Prairie, Minnesota.

For this analysis, end-of-life healthcare costs were examined for 28,530 patients with cancer who died while enrolled in the plan. The most frequent type of malignancy was lung cancer (18% of the cohort). The total cancer-related monthly costs increased as the period before death shortened (Table), from a mean of $7835 during the sixth month before death to more than $25,000 in the last month of life.

Total cancer-related costs over the last 6 months of life were $74,212: $30,254 for outpatient services; $40,702 for acute inpatient hospitalization; and $3256 for hospice. “We only looked at the last 6 months because there’s a misconception that there are a lot of needless drug costs spent in futility. In reality, those costs are minimal compared to the inpatient hospitalizations,” said Teitelbaum.

“Ultimately, cancer-related services cost much much more than any of the drug services could possibly ever cost,” she said. Of the outpatient cancer-related costs:

  • $10,323 was spent on chemo therapy (including biologic and hormonal therapy) and related care (ie, use of erythropoiesis-stimulating agents, granulocyte macrophage colony-stimulating factor)
  • $3710 was for radiation therapy
  • $10,123 was for outpatient services
  • $4040 was for office visits. The $10,323 spent for chemotherapy and related medications accounted for only 13.9% of the total costs over the last 6 months of life.

The use of services such as inpatient hospitalization and hospice care increased noticeably while the use of chemo therapy declined over time, especially during the last 1 to 3 months of life.

“One of the key points is that there needs to be better communication between the physicians, ancillary staff, and the patients and their families in regard to what their wishes are,” said Teitelbaum. “A lot of patients are hesitant to say that they’re not interested in any more care because they’re afraid of abandonment. The term ‘hospice’ has a negative connotation.”

Related Items
Neoantigens Are Effective Targets for Developing Cancer Vaccines
Wayne Kuznar
TOP - November 2019, Vol 12, No 4 published on November 7, 2019 in Emerging Therapies
Repotrectinib, an Investigational TKI, Induces Response in ROS1-Fusion–Positive NSCLC
Wayne Kuznar
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Lung Cancer
Single-Agent ONC201 Induces Responses in Patients with Hard-to-Treat Recurrent High-Grade Glioma
Wayne Kuznar
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Emerging Therapies
NCI-COG Pediatric MATCH Trial Shows High Rate of Targetable Molecular Alterations
Wayne Kuznar
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Pediatric Cancer
Updated NCCN Treatment Guideline for CML Establishes Criteria for Stopping TKI Therapy
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in NCCN
Immunotherapy Strategies in the Updated NCCN Guideline for NSCLC Hinge on PD-L1 Testing
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in NCCN
Updated NCCN Breast Cancer Guideline Expands Treatment Recommendations for HR-Positive, HER2-Negative Disease
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer, NCCN
Immunotherapy Combination Extends Survival in Advanced Refractory Colorectal Cancer
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Colorectal Cancer
Tumor Metabolism-Altering Regimen Achieves Clinical Benefit in Metastatic Pancreatic Cancer
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Pancreatic Cancer
CAR T-Cell Therapy Fills Unmet Needs in Leukemia and Lymphoma
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Immunotherapy
Last modified: September 9, 2019